RENOVA

LOE Approaching

tretinoin

NDATOPICALCREAM
Approved
Aug 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
19

Mechanism of Action

Pharmacologic Class:

Retinoid

Clinical Trials (5)

NCT07341659N/AActive Not Recruiting

Efficacy of Cosmetic Product RV3278B-OS0386 in the Maintenance Phase After Oral Isotretinoin Treatment of Adults Subjects With Facial Acne.

Started Feb 2025
102 enrolled
Acne
NCT04353180Phase 3Unknown

Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized)

Started Aug 2021
100,000 enrolled
COVID19
NCT03596671N/ACompleted

BlueWind RENOVA iStim™ System for the Treatment of OAB

Started Jun 2019
NCT03022019N/ATerminated

ReNovaCell in Non-segmental Vitiligo

Started Dec 2016
17 enrolled
Non-segmental VitiligoVitiligo
NCT02498288Phase 1Completed

A Study to Determine Bioequivalence of Isotretinoin in Healthy Male Subjects Under Fed Condition

Started May 2013
36 enrolled
Acne Vulgaris